Transforming Diabetic Foot Ulcer Treatment with VENDAJE®

Better Processing leads to Better Results

Diabetic foot ulcers (DFUs) pose a daunting challenge for both patients and healthcare
providers, significantly impacting quality of life and increasing the risk of complications.

However, the innovation behind VENDAJE, a dehydrated human amniotic membrane (DHAM) allograft, offers a beacon of hope. VENDAJE’s unique BioREtain process preserves the natural growth factors and cytokines essential for wound healing, making it a game changer in the treatment of DFUs.

Ulcers benefit from the anti-inflammatory and anti-microbial properties of amniotic tissue which not only accelerates tissue regeneration but also reduces the risk of infections—a common and dangerous complication in diabetic patients.

Clinically Effective and Cost-Effective 

Clinical applications have demonstrated that incorporating VENDAJE into a comprehensive
wound care strategy leads to faster healing rates, decreased incidence of infection, and
improved outcomes. This translates into reduced hospital stays and healthcare costs,
making VENDAJE not only a clinically effective option but also a cost-effective one.

Promising Solution for DFUs

For healthcare providers specializing in diabetes and wound care, VENDAJE offers a
promising solution to a prevalent and persistent problem, ensuring better patient
care and enhanced recovery rates

BioREtain Free Evaluation

If you are a wound care professional, and would like to participate in our free evaluation program, please call or email: sales@biostemtech.com to get started today.